Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01424384 | Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic | PHASE1 | COMPLETED | 54 | — | — | Sep 19, 2008 | Apr 30, 2009 | Jul 7, 2017 | 1 | United Kingdom |
| NCT01059591 | First Study in Humans With GSK424887 | PHASE1 | COMPLETED | 26 | — | — | May 25, 2006 | Jan 25, 2007 | Aug 11, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Citalopram | ACTIVE_COMPARATOR | Marketed comparitor |
| Investigational Medicinal Product | EXPERIMENTAL | GSK424887 |
| Placebo To Match Treatment | PLACEBO_COMPARATOR | Placebo control |
| Active | EXPERIMENTAL | GSK424887 once daily |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily |
| Name | Type | Description |
|---|---|---|
| Citalopram | DRUG | Neurophysiological testing. |
| GSK424887 | DRUG | Neurophysiological testing |
| Plactebo To Match | DRUG | Neurophysiological testing |
| Placebo | DRUG | Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule |
| PET | RADIATION | Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose |
Inclusion Criteria: 1. Healthy males with no neurological, or history of psychiatric illness 2. Aged between 18 and 45 years 3. Agree to use contraception 4. BMI range of 18 to 33 kg/m² 5. Fluent English speakers 6. Non smoker or light smoker Exclusion Criteria: 1. Positive pre-study drug/alcohol...